Savica Rodolfo, Grossardt Brandon R, Bower James H, Ahlskog J Eric, Boeve Bradley F, Graff-Radford Jonathan, Rocca Walter A, Mielke Michelle M
Department of Neurology, Mayo Clinic, Rochester, Minnesota2Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
JAMA Neurol. 2017 Jul 1;74(7):839-846. doi: 10.1001/jamaneurol.2017.0603.
To our knowledge, a comprehensive study of the survival and causes of death of persons with synucleinopathies compared with the general population has not been conducted. Understanding the long-term outcomes of these conditions may inform patients and caregivers of the expected disease duration and may help with care planning.
To compare survival rates and causes of death among patients with incident, clinically diagnosed synucleinopathies and age- and sex-matched referent participants.
DESIGN, SETTING, AND PARTICIPANTS: This population-based study used the Rochester Epidemiology Project medical records-linkage system to identify all residents in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010. A movement-disorders specialist reviewed the medical records of each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy. For each confirmed patient, an age- and sex-matched Olmsted County resident without parkinsonism was also identified.
We determined the age- and sex-adjusted risk of death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of death.
Of the 461 patients with synucleinopathies, 279 (60.5%) were men, and of the 452 referent participants, 272 (60.2%) were men. From 1991 through 2010, 461 individuals received a diagnosis of a synucleinopathy (309 [67%] of Parkinson disease, 81 [17.6%] of dementia with Lewy bodies, 55 [11.9%] of Parkinson disease dementia, and 16 [3.5%] of multiple system atrophy with parkinsonism). During follow-up, 68.6% (n = 316) of the patients with synucleinopathies and 48.7% (n = 220) of the referent participants died. Patients with any synucleinopathy died a median of 2 years earlier than referent participants. Patients with multiple system atrophy with parkinsonism (hazard ratio, 10.51; 95% CI, 2.92-37.82) had the highest risk of death compared with referent participants, followed by those with dementia with Lewy bodies (hazard ratio, 3.94; 95% CI, 2.61-5.94), Parkinson disease with dementia (hazard ratio, 3.86; 95% CI, 2.36-6.30), and Parkinson disease (hazard ratio, 1.75; 95% CI, 1.39-2.21). Neurodegenerative disease was the most frequent cause of death listed on the death certificate for patients, and cardiovascular disease was the most frequent cause of death among referent participants.
Individuals with multiple system atrophy with parkinsonism, dementia with Lewy bodies, and Parkinson disease dementia have increased mortality compared with the general population. The mortality among persons with Parkinson disease is only moderately increased compared with the general population.
据我们所知,尚未对与普通人群相比的突触核蛋白病患者的生存率和死亡原因进行全面研究。了解这些疾病的长期预后情况可以让患者和护理人员知晓预期的疾病持续时间,并有助于护理规划。
比较初发的、临床诊断为突触核蛋白病的患者与年龄和性别匹配的对照参与者的生存率和死亡原因。
设计、地点和参与者:这项基于人群的研究使用了罗切斯特流行病学项目医疗记录链接系统,以识别明尼苏达州奥尔姆斯特德县1991年至2010年间所有获得帕金森综合征诊断代码的居民。一名运动障碍专家查阅了每个人的医疗记录,以确认帕金森综合征的存在并确定突触核蛋白病的类型。对于每一位确诊患者,还确定了一名年龄和性别匹配的无帕金森综合征的奥尔姆斯特德县居民作为对照。
我们确定了每种类型突触核蛋白病的年龄和性别调整后的死亡风险、从诊断到死亡的中位时间以及死亡原因。
在461例突触核蛋白病患者中,279例(60.5%)为男性,在452例对照参与者中,272例(60.2%)为男性。从1991年到2010年,461人被诊断为突触核蛋白病(帕金森病309例[67%]、路易体痴呆81例[17.6%]、帕金森病痴呆55例[11.9%]、帕金森叠加型多系统萎缩16例[3.5%])。在随访期间,68.6%(n = 316)的突触核蛋白病患者和48.7%(n = 220)的对照参与者死亡。任何突触核蛋白病患者的死亡中位时间比对照参与者早2年。与对照参与者相比,帕金森叠加型多系统萎缩患者(风险比,10.51;95%置信区间,2.92 - 37.82)的死亡风险最高,其次是路易体痴呆患者(风险比,3.94;95%置信区间,2.61 - 5.94)、帕金森病痴呆患者(风险比,3.86;95%置信区间,2.36 - 6.30)和帕金森病患者(风险比,1.75;95%置信区间,1.39 - 2.21)。神经退行性疾病是患者死亡证明上列出的最常见死因,而心血管疾病是对照参与者中最常见的死因。
帕金森叠加型多系统萎缩、路易体痴呆和帕金森病痴呆患者的死亡率高于普通人群。帕金森病患者的死亡率与普通人群相比仅适度增加。